The current board is composed of nine members and is led by founder and chair of the board of directors, Mariam S. Darsot.
The appointments come as Nexus works to expand its offerings to include new products as well as Nexus Pharma Services.
Lee is the Founder and Managing Member of Sagent Group and brings over twenty years of experience investing in and advising companies in the life sciences and technology, media, and telecommunications industries.
Prior to the founding of Sagent Group, he served as the founder and portfolio manager of Oaktree's USD 6bn Strategic Credit strategy as well as serving as CEO and CIO of the organization's three business development companies.
Lee also brings experience from his work in TMT investment banking at UBS in Los Angeles, fixed income at Lehman Brothers, management consulting at Katzenbach Partners (Booz & Co.) and economic research at the Urban Institute.
He holds a B.A. degree in economics from Swarthmore College and a master's degree from Harvard University.
Warmuth was most recently an Operating Partner at EW Healthcare Partners from 2018 to 2022.
Prior to EW Healthcare Partners, Warmuth was at Abbott Laboratories, where he led the Established Pharmaceuticals division which soon became one of the top ten largest generics companies across the globe and covered several therapeutic areas including gastroenterology, women's health, cardiovascular, and metabolic disorders.
His work at Abbott reflects a strong track record of success in driving operational excellence and growth through mergers and acquisitions. He holds a B.A. degree in Business Administration from the University of Wisconsin-Whitewater and a master's degree from Northwestern University.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling